Form 8-K - Current report:
SEC Accession No. 0001610618-17-000052
Filing Date
2017-10-20
Accepted
2017-10-19 18:30:40
Documents
4
Period of Report
2017-10-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cdtx8-k2017x10x19.htm 8-K 28393
2 SECURITIES PURCHASE AGREEMENT ex101-securitiespurchaseag.htm EX-10.1 346166
3 PRESS RELEASE ex991-pressrelease2017x10x.htm EX-99.1 9090
4 cdtxlogosec.jpg GRAPHIC 63449
  Complete submission text file 0001610618-17-000052.txt   472383
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 171145548
SIC: 2836 Biological Products, (No Diagnostic Substances)